Breast Milk Biomimetic Nano Particles as a Versatile, Non-Invasive, Oral Drug Delivery Tool

The project aims to engineer MILKOSOMES from human breast milk cells to enhance oral drug delivery by protecting therapeutic agents and improving their gastrointestinal absorption.

Subsidie
€ 2.437.500
2024

Projectdetails

Introduction

We propose to use human breast milk cells to engineer breast milk biomimetic nanoparticles (NP), “MILKOSOMES,” to shuttle medicines orally into the body that, under other conditions, would not be able to distribute properly. MILKOSOMES are cellular membrane protein-functionalized phospho-lipid NP (i.e., liposomes), and they are hypothesized to cross the gastrointestinal (GI) tract while protecting their therapeutic cargo and serve as a novel way to improve oral therapy outcomes.

Challenges of Oral Delivery

Unfortunately, although oral delivery of therapeutic agents is the most patient-preferred route of administration because it is painless and convenient, it entails enormous challenges. Specifically, large molecules, such as messenger RNA and proteins, cannot be delivered orally due to their chemical and enzymatic degradation in the GI tract and poor intestine's permeability to these molecules.

Unique Properties of Cells

Interestingly, cells, which are a thousand times bigger than these large molecules, remain intact. Therefore, they can get out of the GI tract due to membrane protein-mediated biological processes and make their way into our bodies.

Objectives

Herein, we aim to:

  1. Identify and assess the breast milk cell populations which cross the GI tract into the infant body after breastfeeding in vivo.
  2. Fabricate and characterize MILKOSOMES.
  3. Evaluate MILKOSOMES’ ability to cross the GI tract biological barrier using in vitro and ex-human models.
  4. Test MILKOSOMES’ therapeutic efficacy in vivo using two diverse in vivo models.

Conclusion

Thus, we will harness the specific and unique biological function of these GI tract-crossing native cells while protecting their therapeutic cargo from degradation using the phospho-lipid NP backbone. Our findings will increase our fundamental understanding of cellular and NP trafficking through the GI tract and lay the foundations for designing a next generation and non-invasive nano-biomimetic oral drug delivery technology that may affect public health worldwide.

Financiële details & Tijdlijn

Financiële details

Subsidiebedrag€ 2.437.500
Totale projectbegroting€ 2.437.500

Tijdlijn

Startdatum1-3-2024
Einddatum28-2-2029
Subsidiejaar2024

Partners & Locaties

Projectpartners

  • TECHNION - ISRAEL INSTITUTE OF TECHNOLOGYpenvoerder

Land(en)

Israel

Vergelijkbare projecten binnen European Research Council

ERC STG

MANUNKIND: Determinants and Dynamics of Collaborative Exploitation

This project aims to develop a game theoretic framework to analyze the psychological and strategic dynamics of collaborative exploitation, informing policies to combat modern slavery.

€ 1.497.749
ERC STG

Elucidating the phenotypic convergence of proliferation reduction under growth-induced pressure

The UnderPressure project aims to investigate how mechanical constraints from 3D crowding affect cell proliferation and signaling in various organisms, with potential applications in reducing cancer chemoresistance.

€ 1.498.280
ERC STG

The Ethics of Loneliness and Sociability

This project aims to develop a normative theory of loneliness by analyzing ethical responsibilities of individuals and societies to prevent and alleviate loneliness, establishing a new philosophical sub-field.

€ 1.025.860
ERC STG

Uncovering the mechanisms of action of an antiviral bacterium

This project aims to uncover the mechanisms behind Wolbachia's antiviral protection in insects and develop tools for studying symbiont gene function.

€ 1.500.000

Vergelijkbare projecten uit andere regelingen

ERC POC

Versatile Polypeptide-based Intranasal Drug Delivery Platform(s) to Tackle CNS Disorders.

POLYBRAINT aims to develop an innovative intranasal drug delivery platform to effectively transport biological agents across the blood-brain barrier for treating CNS disorders.

€ 150.000
ERC POC

Modification of liposomic nano-carriers: a novel strategy for improved drug-delivery and eradication of bacterial biofilms

This project aims to develop and evaluate a novel drug delivery system to effectively treat and eradicate bacterial biofilms, addressing significant health and economic challenges.

€ 150.000
ERC POC

Novel functionalization of liposomic nano-vehicles for strongly-enhanced drug delivery

This project aims to innovate lipid-based drug delivery by developing novel functionalization methods to enhance therapeutic efficiency while overcoming PEGylation drawbacks.

€ 150.000
ERC ADG

Functional Nanoscale Therapeutics

Develop functional hybrid nanoscale medicines to enhance intracellular delivery of mRNA and combat nanoscale pathogens, aiming for advanced therapies against diseases like cancer.

€ 2.499.796